Have Changing Palivizumab Administration Policies Led to More Respiratory Morbidity in Infants Born at 32-35 Weeks?
Have Changing Palivizumab Administration Policies Led to More Respiratory Morbidity in Infants Born at 32-35 Weeks?
复制标题
改变帕利珠单抗给药政策是否会导致 32-35 周出生婴儿的呼吸系统发病率更高？
DOI：
10.1016/j.jpeds.2015.11.040
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
Hibbs,AnnaMaria
中科院分区：
文献类型：
--
作者：
Olicker,Arielle;Li,Hong;Tatsuoka,Curtis;Ross,Kristie;Trembath,Andrea;Hibbs,AnnaMaria
ObjectivesTo determine differences in the incidence of respiratory morbidity during the first year of life among infants born 320/7-346/7weeks' gestational age (GA) before and after the administration policy for palivizumab, as written by the American Academy of Pediatrics, was updated in 2009.Study designSecondary analysis of the dataset collected for the Gastrointestinal Risk Factors for Wheezing in Premature Infants study, which enrolled preterm infants without bronchopulmonary dysplasia and followed them by parental questionnaires at 3, 6, 9, and 12 months adjusted age for prematurity. Participants were included if they were enrolled in Gastrointestinal Risk Factors for Wheezing in Premature Infants, born 320/7-346/7weeks' GA, and completed the 12-month questionnaire. We compared rates of recurrent wheezing, respiratory medication use, and health care use before (Epoch 1) and after (Epoch 2) the 2009 administration policy change.ResultsA total of 165 infants met inclusion criteria. There was a significant increase in recurrent wheezing in Epoch 2 (46.2%) vs Epoch 1 (28.8%) (OR 2.22 [95% CI 1.08-4.53],P= .03). There was a nonsignificant increase in visits to the emergency department in Epoch 2 (27.4%) vs Epoch 1 (15.3%) (OR 2.12 [95% CI 0.91-4.96],P= .08). There were no differences in hospital admissions or respiratory medication use.ConclusionsInfants born 320/7-346/7weeks' GA treated after the American Academy of Pediatrics administration policy change in 2009 had a greater incidence of recurrent wheezing than those treated according to the previous policy. It will be important to track rates of recurrent wheezing after the 2014 administration policy, because it may be an important factor in future cost-effectiveness analyses.
